Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 82

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 82
---
 the applicable Percentage Spread established in the Credit Line.The Credit Line is secured by a first priority lien and security interest in certain of the Company's assets, including each account of the Company at UBS Financial Services Inc. (the Collateral Account), and other such collateral (collectively, the Collateral), as further defined in the Credit Line. The Company may be required to post additional collateral if the value of the Collateral declines below the required collateral maintenance requirements. Upon certain customary events of default, all amounts due under the Credit Line will become immediately due and payable without demand, and UBS has the right, in its discretion, to liquidate, transfer, withdraw or sell all or any part of the Collateral and apply the proceeds to repay any borrowings pursuant to the Credit Line.The Company has the right to repay any variable rate advance under the Credit Line at any time, in whole or in part, without penalty. The Company may repay any fixed rate advance in whole, but may not repay any fixed rate advance in part. In its discretion and without cause, UBS has the right at any time to demand full or partial payment of amounts borrowed pursuant to the Credit Line and terminate the Credit Line.

As of June 30, 2025 and December 31, 2024, there was no outstanding debt under the Credit Line. 

15

9.    Share-Based Payments

Share-based compensation expense is as follows (dollars in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Research and development$1,479 $1,231 $2,891 $2,596 Selling, general and administrative6,028 5,321 12,684 9,853 Total$7,507 $6,552 $15,575 $12,449 Stock Option The following table summarizes stock option activities:Number ofOptionsWeighted AverageExercise PriceWeightedAverageRemainingContractualTerm (in years)Outstanding, December 31, 20246,719,073 $30.44 5.9Granted 1,081,220 $33.82 Exercised (175,748)$23.01 Forfeited (97,131)$34.37 Outstanding, June 30, 2025 (unaudited)7,527,414 $31.04 6.1As of June